From: Defining the optimal dose of radiation in leukemic patients with extramedullary lesions
Factors ( 2 × 2 analysis) | CR (15 sites) | Non-CR (27 sites) | Total | p -value | |
---|---|---|---|---|---|
Primary disease | Yes | 10 | 17 | 27 | 0.810 |
AML | No | 5 | 10 | 15 | Â |
RT site | Yes | 9 | 7 | 16 | 0.029* |
Soft tissue | No | 6 | 20 | 26 | Â |
Concurrent | Yes | 3 | 7 | 10 | 1.000 |
Chemotherapy | No | 12 | 20 | 32 | Â |
Initial size | Yes | 0 | 7 | 7 | 0.038* |
BP ≥ 30 cm2 | No | 15 | 20 | 35 |  |
Initial size | Yes | 1 | 12 | 13 | 0.015* |
LD ≥ 6.0 cm | No | 14 | 15 | 29 |  |
Follow up time | Yes | 13 | 17 | 30 | 0.158 |
≥ 2 weeks | No | 2 | 10 | 12 |  |
Total dose | Yes | 8 | 9 | 17 | 0.326 |
≥ 25 Gy | No | 7 | 18 | 25 |  |
BED10 | Yes | 8 | 10 | 18 | 0.347 |
≥ 30 Gy | No | 7 | 17 | 24 |  |